TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Eureka Therapeutics Collaborates with UCSF Benioff Children’s Hospitals for ARYA-2 Clinical Trial Focusing on Pediatric Liver Cancers in California

Wednesday, April 03, 2024

Eureka Therapeutics, Inc., a leading biotechnology firm focused on developing innovative T-cell therapies for cancer treatment, has announced that UCSF Benioff Children’s Hospitals is now the first site in California to participate in the ARYA-2 clinical trial (NCT04634357).

The ARYA-2 trial is evaluating Eureka’s ARTEMIS® ET140203 T-cell therapy, which targets the alpha-fetoprotein (AFP)-peptide/HLA-A2 complex. This therapy is intended for pediatric patients (1 to 21 years old) with relapsed or refractory liver cancer, including hepatoblastoma (HB), hepatocellular neoplasm not otherwise specified (HCN-NOS), and hepatocellular carcinoma (HCC).

According to Dr. Arun Rangaswami, MD, Professor of Clinical Pediatrics and a senior solid tumor faculty member at UCSF, the treatment options for children and adolescents with multiply relapsed or refractory liver cancers are limited. He expressed excitement about collaborating with Eureka to provide next-generation engineered T-cell therapy to this pediatric population facing significant medical challenges.

Dr. Abla Creasey, PhD, Vice President of Therapeutics Development at the California Institute for Regenerative Medicine (CIRM), emphasized their commitment to supporting the development of therapies for pediatric cancer patients, including their recent grant of $10.6 million towards Eureka’s ARYA-2 program.

Dr. Cheng Liu, President and CEO of Eureka Therapeutics, highlighted the significance of UCSF's participation in accelerating the progress of bringing this potentially life-saving therapy to young patients with liver cancer.

This expansion of the trial builds upon Eureka’s ongoing efforts, with the ARYA-2 trial also actively recruiting patients at the Dana-Farber Cancer Institute. For more information about the ARYA-2 trial, Eureka’s T-cell therapy platform, and the potential of this treatment.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit